PR-104

PR-104 is a bioreductive prodrug designed to be activated in hypoxic conditions, a common feature of many types of solid tumors. It was developed by the University of Auckland and is currently being investigated for its potential use in cancer therapy.

History

PR-104 was first synthesized by researchers at the University of Auckland in New Zealand. The development of PR-104 was based on the concept of hypoxia, a condition in which there is a decrease in the oxygen supply to a tissue. Hypoxia is a common feature of many types of solid tumors and is associated with resistance to conventional therapies.

Mechanism of Action

PR-104 is a bioreductive prodrug, which means it is converted into its active form in the body. The conversion of PR-104 to its active form is facilitated by enzymes that are present in higher concentrations in hypoxic cells. The active form of PR-104 then interferes with the DNA of the cancer cells, preventing them from replicating and causing them to die.

Clinical Trials

PR-104 has been tested in several clinical trials for various types of cancer, including leukemia, non-small cell lung cancer, and soft tissue sarcoma. The results of these trials have shown that PR-104 has potential as a treatment for these types of cancer, particularly in patients who have not responded to other treatments.

Future Research

Future research on PR-104 will focus on further understanding its mechanism of action and determining the most effective way to use it in cancer therapy. This may involve combining PR-104 with other treatments or using it as a second-line treatment in patients who have not responded to other therapies.

This article is a stub related to pharmacology. You can help WikiMD by expanding it!